Framingham Union Hospital/MetroWest Medical Center
Framingham, Massachusetts, 01702, United States
Location contact
Chih-Hsien Wu, M.D.
CONTACT
Eric Silverman, M.D.
CONTACT
NCT Number: NCT07293078
This is a prospective, unmasked, randomized, multicenter clinical trial evaluating the impact of point-of-care large language model (LLM)-based decision support on diagnostic accuracy and clinical outcomes in adult medical intensive care unit (MICU) patients.
Consecutive adult ICU admissions at participating community hospitals (initially MetroWest Medical Center and St. Vincent Hospital) will be screened for eligibility. Eligible patients will be randomized 1:1 to standard care or an AI-assisted group. In both arms, initial evaluation and management will follow usual practice. For patients randomized to AI assistance, de-identified admission data (history and physical, labs, imaging reports, and other relevant documentation) will be formatted and submitted to a state-of-the-art LLM (ChatGPT-5) at the time of admission. The AI-generated differential diagnosis and therapeutic recommendations will be provided to the admitting team for consideration. For the standard care arm, LLM output will be generated but not shared with clinicians.
After discharge, a masked chart review will determine the "ground truth" primary diagnosis and extract outcomes including: Primary Outcome - a composite of medical errors (from time of ICU admission through day 7 of ICU stay, or ICU discharge, whichever comes first); Secondary Outcomes - 90-day mortality, ICU and hospital length of stay, and ventilator-free days.
Trial opening soon.
Get Notified18 year and older
All sexes
Interventional
Phase 1 / Phase 2
Framingham, Massachusetts, 01702, United States
Chih-Hsien Wu, M.D.
CONTACT
Eric Silverman, M.D.
CONTACT
The rapid development of large language models (LLMs) such as ChatGPT has created new opportunities and risks for their use in medicine. Although early studies suggest high diagnostic accuracy in complex clinical scenarios and ICU admissions, the impact of LLMs on real-world clinical outcomes and the optimal mode of physician-AI interaction remain uncertain. Published work from our group showed that ChatGPT-4 achieved diagnostic accuracy comparable to board-certified intensivists for ICU admissions in a retrospective study. However, prospective, randomized data on clinical outcomes are lacking.
This trial will evaluate a pragmatic paradigm for integrating LLMs at the time of ICU admission (point-of-care AI). All eligible adult MICU admissions at participating sites will be prospectively randomized to: (1) standard care, or (2) AI-assisted care in which an LLM receives standardized, de-identified admission data and returns a proposed primary diagnosis, ranked differential diagnosis (up to five conditions), suggested additional information, and prioritized therapeutic interventions. Admitting clinicians in the AI-assisted arm will be asked to review and optionally incorporate the AI recommendations and will complete a brief questionnaire regarding perceived utility and any changes in diagnosis or management.
A masked clinical adjudication panel will perform longitudinal chart review to define the "ground truth" primary diagnosis and assess error rates and outcomes. The primary endpoint is a composite of medical errors. The specific time frame will be from the time of ICU admission through day 7 of ICU stay, or ICU discharge, whichever comes first. Secondary endpoints will include 90-day mortality, ICU and hospital length of stay, and ventilator-free days. Other exploratory secondary endpoints will be considered. The trial is designed to enroll approximately 1000 patients across multiple MICUs, with interim analysis at 12 months to assess feasibility, integrity, and futility. The study is minimal risk, uses de-identified data for AI queries, and does not alter standard diagnostic testing or therapeutic options.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Use of a large language model (ChatGPT-5) to analyze de-identified ICU admission data (history, physical examination, laboratory results, imaging reports, and other documentation) at the time of admission. The model generates diagnostic and therapeutic recommendations that are shared with clinicians in the AI-assisted arm only.
Time frame: From the time of ICU admission through day 7 of ICU stay or ICU discharge, whichever comes first.
Proportion of patients with at least one clinically important diagnostic or therapeutic error identified by masked chart review (e.g., missed or delayed critical diagnosis, major guideline-discordant therapy with potential for harm).
Time frame: 90 days from ICU admission.
All-cause mortality within 90 days of index ICU admission, as determined by chart review and available follow-up records.
Time frame: From ICU admission to ICU discharge (up to 90 days).
Total number of days spent in the ICU during the index hospitalization.
Time frame: Up to 28 days after ICU admission.
Number of days alive and free from invasive mechanical ventilation during the first 28 days after ICU admission.
Time frame: From hospital admission to hospital discharge (up to 90 days).
Total number of days from hospital admission to hospital discharge during the index hospitalization.
Contact information is provided by the study sponsor or research team.
MetroWest Artificial Intelligence Research Workgroup
Other
Prospective Evaluation of a Point-of-Care Artificial Intelligence Model in Critical Care Outcomes
Acronym: POC-AI-ICU
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01753024
Acute Kidney Injury, Acute Renal Failure
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT07472452
Acute Kidney Injury, Critical Illness
View Trial DetailsNCT07658001
Critical Illness, Disease Attributes
Querétaro City, Querétaro, Mexico
View Trial DetailsNCT06193980
Behavior, Critical Illness
Winnipeg, Manitoba, Canada
View Trial Details